摘要
目的进一步规范抗IgE单克隆抗体治疗过敏性哮喘的合理应用。方法通过系统检索和临床经验总结抗IgE单克隆抗体治疗管理的相关问题,按照证据分级进行质量评价,并运用德尔菲法就共识建议达成共识,形成《抗IgE单克隆抗体治疗过敏性哮喘的医药共管专家共识》(简称《共识》)。结果《共识》以奥马珠单抗为代表,形成了12条建议,涵盖了医药共管的工作模式、工作路径、分级诊疗和培训考核等内容,明确奥马珠单抗治疗过敏性哮喘医药共管的规范化管理路径。结论该《共识》为药师参与奥马珠单抗治疗过敏性哮喘的管理提供切实有效的建议,有助于提高患者的用药依从性和疾病预后,实现抗IgE单克隆抗体的医疗价值。
Objective To further standardize the rational use of anti-IgE monoclonal antibody treatment for allergic asthma.Methods Related issues in anti-IgE monoclonal antibody treatment management were identified through systematic reviews and clinical experience.A quality assessment was conducted using evidence grading system,and the Delphi method was employed to establish consensus recommendations,developed expert consensus on physician-pharmacist collaborative management of anti-IgE monoclonal antibody treatment for allergic asthma(referred to as the Consensus).Results The consensus,represented by the omalizumab,formulated 12 recommendations,encompassing the work model of physician-pharmacist collaborative management,clinical pathways,hierarchical diagnosis and treatment systems,and training and assessment.It provided a standardized management framework for physician-pharmaceutical collaborative management of omalizumab treatment in allergic asthma.Conclusion This consensus provides practical recommendations for pharmacists to engage in omalizumab treatment management,aiming to improve patients’medication compliance and disease prognosis,and optimize the clinical value of anti-IgE monoclonal antibody.
出处
《医药导报》
北大核心
2025年第8期1185-1198,共14页
Herald of Medicine
基金
广州市科技计划项目-2024年度市校(院)企联合资助项目(2024A03J1135)。
关键词
过敏性哮喘
医药共管
抗IgE单克隆抗体
奥马珠单抗
Allergic asthma
Physician-pharmacist collaborative management
Anti-IgE monoclonal antibody
Omalizumab
